BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/15/2023 1:46:53 PM | Browse: 96 | Download: 205
 |
Received |
|
2023-05-23 09:54 |
|
Peer-Review Started |
|
2023-05-23 09:56 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2023-07-31 17:22 |
|
Revised |
|
2023-08-31 22:23 |
|
Second Decision |
|
2023-10-11 01:11 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2023-10-11 06:05 |
|
Articles in Press |
|
2023-10-11 06:05 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2023-11-06 09:55 |
|
Publish the Manuscript Online |
|
2023-11-15 13:46 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Mitomycin C and capecitabine: An additional option as an advanced line therapy in patients with metastatic colorectal cancer
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Gil Mullin, Michal Sternschuss, Yosef Landman, Aaron Sulkes and Baruch Brenner |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Baruch Brenner, MD, Professor, Department of Oncology, Davidoff Cancer Center, Beilinson Campus, 39 Jabotinski Street, Petah-Tikva 4941492, Israel. brennerb@clalit.org.il |
| Key Words |
Colorectal cancer; Metastatic cancer; Chemotherapy; Mitomycin C; Capecitabine; Advanced line treatment |
| Core Tip |
Survival with metastatic colorectal cancer has improved significantly. However, when the disease becomes refractory, patients are left with limited options. Mitomycin C (MMC) and capecitabine combination is a potential treatment option for mCRC patients beyond standard lines of treatment. Only a few small studies have tested it in the advanced-line setting, with contradictory results. We present our experience using the MMC/capecitabine combination. Our findings suggest that MMC/capecitabine is a safe, well-tolerated regimen. Ours is the largest series on the use of MMC/capecitabine in refractory mCRC. We were able to identify well-defined subgroups which derived clinical benefit from this combination. |
| Publish Date |
2023-11-15 13:46 |
| Citation |
Mullin G, Sternschuss M, Landman Y, Sulkes A, Brenner B. Mitomycin C and capecitabine: An additional option as an advanced line therapy in patients with metastatic colorectal cancer. World J Gastrointest Oncol 2023; 15(11): 1913-1924 |
| URL |
https://www.wjgnet.com/1948-5204/full/v15/i11/1913.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v15.i11.1913 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
